topic 3b Flashcards

1
Q

how should the industry respond to challenges

A

with productivity and efficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

why should be adopt new technologies

A

to better understand bio and chem

digital technology

personalisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

highlight challenges to the industry

A
  • drive to increase productivity (reverse EROOMS law)
  • patent cliff ( competition with generic drugs once patent expires causing a fall in revenue )
  • diseases may challenge funding models (rare diseases or antibiotics)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

technology

A

high throughput

received lots of hype in early 2000s
parallel synthesis
lab automation
screening of compound libraries

some aspects are still used but some have been improved

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

industry 4.0 principle applications

A

cyber physical system ( machine computer data,, automation,, digital twins,, digitalisation,, big data)

applied to pharma development and manufacturing (pharma 4.0)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is pharma 4.0 tho

A

helps pharmaceutical companies transition to digitisation era

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

smart manufacturing,, 4th industrial revolution

A

pharma 4.0 allows creation of smart factories

lots of advanced sensors and robotics

enable better decision making

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

internet of things + forth industrial revolution

A

internet of things

plays a crucial role in pharma 4

involving ai and machine learning into production facilities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

data analysis and 4th industrial revolution

A

sensors on factory floor collecting data.

helps reduce equipment downtime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

automation and machine learning,, forth industrial revolution

A

increases responsiveness and efficiencies to customers

replacing manual inspection and ai reduces manufacturing errors and saves money + time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

connectivity and advanced engineering

A

industry 4.0 brings disruptive tech like VR, robotics and automation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

outsourcing meaning

A

getting goods or services from an outside provider

  • CRO CMO CDMO
  • normally in countries with lower wages
  • outside provider may have specific specialisms (synthesis, assays, formulation, manufacturing apis)
  • also virtual pharma companies (outsource research and development)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

collabsssss

A
  • big pharma + pre competitive collaboration (to share costs for technology development)
  • with small // biotech companies (which provide specialised expertise in technology or disease areas) basically provide the pharma company with their expertise
  • partnering with academia //non profits (to access basic research)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

in licensing

A

when a company receives the rights to a product or technology or ip from another company

  • right to develop a compound
  • right to use a technology

pay for legal rights from external organisations

allows them to avoid risk (early stage work is done by another company!!)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

acquisition

A
  • take overs and merges
  • consolidate duplicated operations to reduce costs
  • restock pipeline
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

divestment out licensing

A

dispose none core assets or product for others to use.
(generics, OTC drugs,, consumer goods)

  • licence out compounds that are not going to be developed in house (for new disease areas)
17
Q

new modalities

A

new types of molecule, mode of action or novel targets

  • biologics
  • undruggable targets ( protein protein interactions
  • gene therapy
  • rna
18
Q

personalised medicine

A

in well defined patient populations
- bio markers for disease and adverse drug reactions
- treatments targeted to patients
- improves efficacy and safety

requires a greater level of patient involvement in earlier drug development

19
Q

other industry changes

A

repositioning

new business and financial models

20
Q

repositioning

A

applying for an existing compound for a different disease

21
Q

new business and financial models

A

for rare diseases and antibiotics

to couple drugs with devices,, software,, and diagnostics